Advertisement

Topics

FDA Gives AstraZeneca’s Lumoxiti a Thumbs-up for Hairy Cell Leukemia

20:00 EDT 13 Sep 2018 | BioSpace

AstraZeneca and its research-and-development arm, MedImmune, announced that the U.S. FDA approved Lumoxiti (moxetumomab pasudotox-tdfk) for adults with relapsed or refractory hairy cell leukemia (HCL) who have had at least two previous systemic therapies, including with a purine nucleoside analog.

Original Article: FDA Gives AstraZeneca’s Lumoxiti a Thumbs-up for Hairy Cell Leukemia

NEXT ARTICLE

More From BioPortfolio on "FDA Gives AstraZeneca’s Lumoxiti a Thumbs-up for Hairy Cell Leukemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...